Doubling the RAS Blockade: A Bad ALTITUDE

This F1000 commentary reports on the ALTITUDE study, which concluded that combination blockade of the RAS should not be used in people with diabetes and CKD.

Source: Medscape Cardiology Podcast - March 1, 2013 Category: Cardiology Authors: Medscape Source Type: podcasts